Here's what nobody talks about: The same lipid nanoparticle that delivers mRNA vaccines could deliver gene therapies, siRNA, or small molecule drugs—but we develop each application as if it's a completely new drug. This is backwards. Platform carriers should be regulated like reusable excipients, not reinvented for every payload.
The Current Insanity
BIOS research reveals the regulatory duplications: Moderna's LNP system underwent full CMC characterization for COVID vaccines. Pfizer's nearly identical LNP system underwent separate, parallel CMC development. Now Intellia, Alnylam, and others are developing "novel" LNP systems that are 95% identical to established platforms.
Each company treats their delivery vehicle as proprietary IP. Each regulatory submission treats the carrier as a new molecular entity. Each manufacturing process gets developed from scratch. The result: 10x higher costs and 5+ year delays for functionally equivalent delivery systems.
The Platform Logic
Notice what works in other industries:
- Automotive: Chassis platforms shared across multiple models
- Electronics: Standard form factors enable component interoperability
- Software: APIs enable application development without rebuilding infrastructure
Pharma could follow the same approach. Establish regulatory-approved delivery platforms. Optimize manufacturing at scale. Enable payload-focused development without carrier reinvention.
























